Dr. Glyn Jones: Elevating Tissue Intelligence Through Clinical Precision at Kent Imaging 

Chronic wounds and compromised tissue remain among the most complex challenges in modern medicine, affecting millions of patients worldwide and costing healthcare systems billions annually. For plastic and reconstructive surgeons, the stakes are particularly high—tissue viability can determine whether a graft succeeds, a limb is saved, or complications escalate. Clinical decisions often hinge on subtle visual cues, experience, and timing. Yet traditional assessment methods leave room for uncertainty. 

As a plastic surgeon and MD–CMO at Kent Imaging, Dr. Glyn Jones brings firsthand surgical insight to the forefront of medical innovation. His perspective is grounded in the operating room, where precision, evidence, and outcome accountability are non-negotiable. This dual role uniquely positions him to ensure that emerging imaging technologies are not just technologically advanced, but clinically indispensable. 

At Kent Imaging, Dr. Jones’ leadership centers on validating tissue imaging solutions that provide objective, real-time data on oxygenation and perfusion—critical indicators in reconstructive and wound care procedures. Rather than relying solely on subjective visual assessments, clinicians can access quantifiable insights that strengthen decision-making and reduce uncertainty. 

By integrating surgical expertise with medical strategy, Dr. Jones is helping redefine how tissue health is evaluated across specialties. His work is transforming imaging from a supportive diagnostic tool into a proactive clinical asset—reshaping standards of care and advancing a more precise, data-driven future for reconstructive medicine and beyond. 

Clinical Expertise Shaping Strategic Direction 

With decades of experience in plastic and reconstructive surgery, Dr. Glyn Jones has developed a deep understanding of the real-world challenges clinicians encounter—particularly when making critical decisions about tissue viability and surgical outcomes. His frontline experience allows him to clearly recognize the gaps that exist between clinical need and technological capability. As he often emphasizes, meaningful innovation must begin with a precise understanding of what practitioners require to deliver safer, more predictable care. 

In his role at Kent Imaging, Dr. Jones works closely with business and technical teams to translate that clinical insight into long-term strategic direction. He brings a physician’s lens to corporate decision-making, ensuring that product development and research investments are aligned with tangible clinical value. “Understanding both the demands of the field and the range of emerging technologies allows us to determine which research initiatives are truly worth pursuing,” he notes. This balanced perspective not only guides internal strategy but also sparks new research opportunities that strengthen the company’s scientific and commercial positioning. 

As a physician executive, his credibility is firmly rooted in his accomplishments as a surgeon and in his active role supporting technologies that enhance patient outcomes. By combining surgical authority with executive leadership, Dr. Jones ensures that innovation remains grounded in evidence, practicality, and the ultimate goal of improving clinical decision-making for physicians worldwide. 

Advancing Noninvasive Perfusion Assessment Through Innovation 

Kent Imaging was conceived with a clear clinical mission: to improve wound and surgical outcomes by enabling accurate, noninvasive assessment of tissue perfusion. From the outset, the vision was to create a compact, handheld device that could seamlessly move between office settings, hospital wards, ICUs, and operating rooms—delivering real-time insights wherever clinical decisions are made. As Dr.  Jones explains, meaningful innovation begins with identifying a persistent clinical gap and committing to solving it in a way that enhances both precision and practicality. 

When the company was founded, perfusion assessment options were limited to outdated fluorescein imaging or invasive, high-cost indocyanine green (ICG) angiography platforms such as SPY systems. These technologies were either cumbersome, expensive, or reliant on injectable dyes—factors that restricted widespread use. Developing a near-infrared, noninvasive solution required overcoming significant scientific barriers, particularly the challenge of melanin interference across the full spectrum of Fitzpatrick skin types. Integrating complex optical physics with advanced algorithms capable of interpreting hemoglobin signals represented the company’s greatest technical hurdle. To date, Kent Imaging remains the only team to successfully translate this capability into a clinically viable handheld platform. 

As a plastic surgeon, Dr. Jones recognized early in his career that perfusion assessment is central to successful reconstructive and cosmetic outcomes. “Every surgeon understands that tissue viability determines everything,” he notes. The Kent SnapshotNIR device has transformed that assessment process, offering immediate onboard analytics of tissue oxygenation alongside detailed measurement of oxyhemoglobin and deoxyhemoglobin levels. By providing objective indicators of hypoxia and venous congestion—without invasive dyes or prohibitive costs—the technology has redefined how surgeons evaluate tissue health, making advanced perfusion analysis both accessible and actionable in everyday practice. 

Expanding Access Through Technological Breakthroughs 

Two defining advancements have propelled Kent Imaging to the forefront of noninvasive perfusion and oxygenation imaging. The first was the development of a compact, untethered handheld device designed for real clinical environments. Rather than confining advanced imaging to specialized suites or complex setups, the technology was engineered to move seamlessly from clinic to bedside to operating room. As Dr. Jones explains, “If a technology is not practical at the point of care, its clinical value is inherently limited.” Portability was not simply a design preference—it was a strategic decision to ensure accessibility and workflow integration. 

The second, and perhaps most transformative breakthrough, has been the ability to accurately image across the full spectrum of Fitzpatrick skin types. Near-infrared imaging has historically struggled with melanin interference, limiting meaningful assessment in patients with higher melanin content. By overcoming this technical barrier through sophisticated optical engineering and advanced algorithms, Kent Imaging achieved more than a technical milestone; it reflects a commitment to equitable, clinically reliable assessment for diverse patient populations. In doing so, the company has positioned itself not only as an innovator, but as a leader in inclusive medical technology. 

Innovation Amid Evolving Healthcare Demands 

Kent Imaging’s continued success is rooted in a culture of technological innovation coupled with a willingness to adapt to physicians’ evolving needs. From Dr. Jones’ perspective, sustained relevance in med tech requires constant dialogue with clinicians. “Healthcare is never static,” he notes. “Our responsibility is to anticipate where practice is heading and ensure our technology evolves accordingly.” That adaptability has been central to the company’s long-term strategic direction. 

At the same time, healthcare and med tech leaders face mounting systemic challenges. Escalating cost pressures demand solutions that not only improve outcomes but also contribute to financial sustainability. Technologies that reduce complications, prevent repeat procedures, and minimize unnecessary interventions are no longer optional—they are essential. For Dr. Jones, aligning research and development with cost-conscious care delivery is critical to meaningful innovation. 

Another accelerating trend is miniaturization and integration into advanced surgical platforms, including laparoscopic and robotic applications. As procedures become less invasive and more technologically sophisticated, imaging solutions must keep pace. Kent Imaging continues to explore pathways that align with these advancements, ensuring that perfusion assessment remains compatible with the future of surgery. Through strategic foresight and clinical insight, Dr. Jones helps guide the company toward innovations that are not only technically advanced, but also economically and operationally sustainable. 

Fostering Clinical Excellence Through Continuous Feedback and Inclusive Culture 

At Kent Imaging, a culture of clinical excellence is not an abstract ideal—it is an operational principle embedded into product development and organizational growth. For Dr. Glyn Jones, innovation begins with rigorous evaluation. “We have to be willing to critically assess our own technology,” he emphasizes. “If it does not truly meet the needs of clinicians in their daily practice, then refinement is not optional—it’s essential.” 

This philosophy has shaped the evolution of Kent’s imaging platform. Continuous engagement with frontline clinicians ensures that feedback is not only heard but systematically integrated into product enhancements. Real-world user insights have directly informed improvements in device functionality, usability, and algorithmic interpretation of tissue data. By maintaining an ongoing feedback loop with end users, the company has strengthened both the clinical reliability and practical utility of its technology. For Dr. Jones, this iterative refinement reflects a broader commitment: ensuring that innovation remains dynamic, evidence-based, and responsive to changing healthcare environments. 

Equally central to Kent Imaging’s success is its inclusive and merit-driven workplace culture. Since its inception, the company has actively engaged individuals from diverse backgrounds and disciplines, fostering a collaborative environment where varied perspectives strengthen problem-solving and innovation. Advancement is grounded in merit, and employees are treated with respect and equality. Dr. Jones believes that organizational integrity mirrors clinical integrity—both require transparency, accountability, and openness to critique. By consistently valuing employee feedback and encouraging constructive dialogue, Kent Imaging sustains a culture where both technology and talent continue to evolve together. 

Building an Integrated Portfolio of Intelligent Imaging Solutions 

Over time, Kent Imaging has developed a comprehensive portfolio of products and services tailored to the evolving needs of clinicians in diverse care environments. At the core of this portfolio is its near-infrared multispectral (NIRS) imaging platform, SnapshotNIR, which enables real-time assessment of tissue oxygenation and perfusion. Expanding on this foundation, SnapshotGLO introduced bacterial autofluorescence imaging to support infection detection. 

The company continues to strengthen its ecosystem through seamless integration of imaging data into electronic health records (EHRs), facilitating accurate documentation and longitudinal tracking. Secure data upload capabilities allow clinicians to transfer information from devices to protected servers efficiently, supporting compliance and remote collaboration.  

Kent Imaging’s Research and Development team is expanding its innovation with a suite of solutions reflects Kent Imaging’s commitment to delivering objective, data-driven tools that integrate smoothly into real-world clinical practice. By combining imaging precision, digital connectivity, and user-centered design, the company has established a scalable platform capable of supporting clinicians across outpatient, hospital, and surgical settings. 

Transforming Wound Care and Surgical Decision-Making 

Kent Imaging’s Snapshot technology has had a significant impact in two primary clinical domains: wound management and intraoperative perfusion assessment. In outpatient wound care, the device enables precise measurement of wound dimensions alongside objective evaluation of tissue oxygenation at the bedside. Its portability has extended its use into home health environments, mobile wound care services, and hospital-based practices. By replacing subjective visual assessments with quantifiable metrics, the technology allows clinicians to document baseline tissue status and monitor progress throughout treatment. Ongoing development of clinical algorithms is further enhancing standardized wound management protocols. 

In the surgical sphere, perfusion assessment initially gained prominence in breast reconstruction, where evaluating mastectomy flap viability is critical to patient safety. Historically, reconstruction often required a staged approach involving tissue expansion before final implant placement. With reliable intraoperative perfusion data, surgeons have increasingly transitioned to single-stage, direct-to-implant prepectoral reconstruction when tissue viability permits. This shift has improved aesthetic outcomes, reduced patient discomfort, shortened treatment timelines, and enhanced overall satisfaction and safety. 

Beyond breast reconstruction, the technology is now applied across plastic, orthopedic, general, and neurosurgical procedures involving flap viability and soft tissue evaluation. As Kent Imaging continues to expand its portfolio, the clinical applications of objective perfusion assessment are expected to grow substantially across multiple surgical specialties. 

Advancing Equitable and Accessible Perfusion Imaging 

A defining strength of Kent Imaging lies in its ability to provide a racially agnostic method of assessing tissue perfusion across the full spectrum of Fitzpatrick skin types. This capability, unique within the competitive landscape, represents a significant advancement in equitable care delivery. Dr. Jones emphasizes that reliable imaging must serve every patient population with equal accuracy. “If a device performs well only in a subset of patients, it falls short of true clinical utility,” he notes. By overcoming historical melanin-related limitations in near-infrared imaging, the company has established a new benchmark for inclusive diagnostic precision. 

Looking ahead, the incorporation of multiple imaging modalities within a single handheld platform would further expand clinical applicability while improving affordability. Combining advanced capabilities enhances usability in mobile wound care settings and resource-constrained environments. The competitive price point with the Snapshot portfolio makes the technology particularly attractive in international markets with socialized healthcare systems, as well as in developing regions where cost remains a critical barrier to adoption. By aligning technological sophistication with global accessibility, Kent Imaging continues to position itself at the forefront of practical, scalable medical innovation. 

Expanding Clinical Insight with Bacterial Autofluorescence Imaging 

The recent introduction of SnapshotGLO has meaningfully broadened the clinical utility of Kent Imaging’s platform. By incorporating bacterial autofluorescence imaging, the company has equipped physicians with a more precise method of identifying bacterial burden that may compromise wound healing. According to Dr. Jones, “Early and accurate detection of bacterial contamination changes the trajectory of wound care. It allows intervention at the point of assessment rather than after complications develop.” 

SnapshotGLO enables clinicians to visualize areas of bacterial overgrowth and estimate the relative intensity of contamination. This capability supports more targeted debridement and treatment strategies, reducing reliance on subjective evaluation alone. Instead of waiting for overt clinical signs of infection, physicians can proactively address microbial hotspots during routine wound assessments. 

For end users, this integration strengthens the value of the handheld platform by combining perfusion analysis with microbial detection in a single workflow. The result is a more comprehensive bedside evaluation tool that enhances clinical efficiency and supports improved healing outcomes. By continuously expanding the functional scope of its devices, Kent Imaging reinforces its commitment to delivering practical, data-driven solutions that evolve alongside the complexities of modern wound management. 

Redefining Breast Reconstruction Through Objective Perfusion Assessment 

Throughout his career as a plastic and reconstructive surgeon, Dr. Jones has consistently sought better, more predictive ways to improve surgical outcomes. Early on, he recognized that accurate assessment of tissue perfusion was fundamental to virtually every reconstructive and cosmetic procedure. “It became clear to me that perfusion determines success or failure in many of the operations we perform,” he reflects. Yet the tools available at the time were limited in predictive value. While ICG-based imaging marked a meaningful step forward, it remained invasive, expensive, and restricted by lack of portability. 

The introduction of Snapshot technology from Kent Imaging significantly reshaped his clinical approach. Its noninvasive design, handheld portability, and immediate onboard analytics provided objective perfusion data directly within the surgical workflow. For Dr. Jones, this capability was transformative. Reliable intraoperative perfusion assessment enabled him to help pioneer prepectoral, immediate, direct-to-implant breast reconstruction—moving beyond the traditional two-stage expander-to-implant pathway. 

This shift not only enhanced aesthetic outcomes and reduced patient discomfort but also lowered overall reconstruction costs for hospitals and insurers. Patients benefited from fewer procedures and shorter treatment timelines, while healthcare systems gained efficiency. Through both practice and education, Dr. Jones has used this platform to teach surgeons a practical, evidence-based alternative to conventional techniques—demonstrating how objective imaging can refine surgical strategy and elevate standards of care. 

Pushing Boundaries and Defining a Lasting Legacy 

“I have always been inspired by challenges that appear, at first glance, insurmountable. Throughout my journey in surgery and wound care, the problems that demanded new thinking were the ones that motivated me most. Whether confronting limitations in perfusion assessment or reimagining reconstructive techniques, I have believed that progress begins where comfort ends. Medicine, like any advancing discipline, requires a willingness to question established norms and explore alternative pathways. Taking calculated risks is not optional—it is essential to meaningful innovation. 

As both a surgeon and MD–CMO at Kent Imaging, I have embraced opportunities to think beyond traditional frameworks. Innovation in surgery is not solely about refining technique; it is about integrating technology, data, and evidence to create safer and more predictable outcomes. Every advancement—whether a new reconstructive approach or the development of objective imaging tools—has been driven by the same goal: improving patient care. 

If there is a legacy I hope to leave, it is one defined by a willingness to push boundaries responsibly and thoughtfully. I would like to be seen as someone who challenged convention, helped pioneer new surgical pathways, and contributed to technologies that strengthened patient safety and clinical success. Ultimately, my work has always centered on one principle: advancing medicine in ways that meaningfully improve the lives of the patients we serve.”